Nav: Home

Financial difficulties linked to worse outcomes from cancer treatment

October 10, 2016

LUGANO-COPENHAGEN, Oct. 10, 2016 - Financial difficulties can significantly impact a cancer patient's quality of life during treatment and may even increase their risk of death, according to the results of a pooled analysis presented at the ESMO 2016 Congress in Copenhagen.

"Financial difficulties may impact the outcome for cancer patients even in countries where the national public health system covers most of the expenses, and therefore, it is our mission to understand what are the determinants of such difficulties and whether some of them may be actionable," said principal investigator Dr. Francesco Perrone, director of the Unità Sperimentazioni Cliniche at the National Cancer Institute of Naples, Italy.

Researchers pooled data from 16 prospective multicenter trials in Italy involving a total of 3670 patients with either lung, breast or ovarian cancer, which included the EORTC quality of life C30 questionnaire. Question 28 of this questionnaire asks patients to rate financial difficulties related to their disease or treatment on a scale from 'not at all' to 'very much'.

The analysis showed that financial burden - defined as any financial difficulty reported at baseline -- was present in 26% of patients at baseline, and was associated with a 35% greater risk of a worse global quality-of-life response (p = 0.009).

Furthermore, financial toxicity, defined as a worsening of the financial score in subsequent questionnaire, was observed in 22.5% of the 2735 who filled out a subsequent questionnaire, and was associated with a 20% increase in the risk of death (p = 0.007).

Perrone said the researchers had expected to find an impact on quality of life from financial hardship, but were surprised to see that worsening financial problems during treatment was associated with a higher risk of death over the course of treatment.

"The size of this impact is moderate but not negligible; it is similar in size to the effect that pushed some new drugs into the market over the last twenty years," Dr. Perrone said.

While pointing out that it was not possible to completely disentangle financial toxicity from a worsening of a patient's clinical condition and disease progression, Perrone said the results from this analysis reflect those observed in similar analyses conducted in the US. "Based on common sense, we oncologists should pay attention to the social status and economic possibilities of our patients and try to advise them regarding their rights in terms of public support and respect due to their condition," Perrone said.

Commenting on the study, Dr Nathan Cherny from the Shaare Zedek Medical Center in Jerusalem, said the study demonstrates that even when patients do not have to pay -- for example, when they are participating in a clinical trial -- a significant number of them enter treatment with some degree of financial burden.

"These findings underscore that even in the absence of payment or co-payment of medications, being ill with cancer often has severe and progressive financial impact on patients and their families," Dr Cherny said. "In the absence of substantial supports and benefits, this may not only compromise quality of life but also patient outcomes."
-end-


European Society for Medical Oncology

Related Cancer Articles:

Radiotherapy for invasive breast cancer increases the risk of second primary lung cancer
East Asian female breast cancer patients receiving radiotherapy have a higher risk of developing second primary lung cancer.
Cancer genomics continued: Triple negative breast cancer and cancer immunotherapy
Continuing PLOS Medicine's special issue on cancer genomics, Christos Hatzis of Yale University, New Haven, Conn., USA and colleagues describe a new subtype of triple negative breast cancer that may be more amenable to treatment than other cases of this difficult-to-treat disease.
Metabolite that promotes cancer cell transformation and colorectal cancer spread identified
Osaka University researchers revealed that the metabolite D-2-hydroxyglurate (D-2HG) promotes epithelial-mesenchymal transition of colorectal cancer cells, leading them to develop features of lower adherence to neighboring cells, increased invasiveness, and greater likelihood of metastatic spread.
UH Cancer Center researcher finds new driver of an aggressive form of brain cancer
University of Hawai'i Cancer Center researchers have identified an essential driver of tumor cell invasion in glioblastoma, the most aggressive form of brain cancer that can occur at any age.
UH Cancer Center researchers develop algorithm to find precise cancer treatments
University of Hawai'i Cancer Center researchers developed a computational algorithm to analyze 'Big Data' obtained from tumor samples to better understand and treat cancer.
New analytical technology to quantify anti-cancer drugs inside cancer cells
University of Oklahoma researchers will apply a new analytical technology that could ultimately provide a powerful tool for improved treatment of cancer patients in Oklahoma and beyond.
Radiotherapy for lung cancer patients is linked to increased risk of non-cancer deaths
Researchers have found that treating patients who have early stage non-small cell lung cancer with a type of radiotherapy called stereotactic body radiation therapy is associated with a small but increased risk of death from causes other than cancer.
Cancer expert says public health and prevention measures are key to defeating cancer
Is investment in research to develop new treatments the best approach to controlling cancer?
UI Cancer Center, Governors State to address cancer disparities in south suburbs
The University of Illinois Cancer Center and Governors State University have received a joint four-year, $1.5 million grant from the National Cancer Institute to help both institutions conduct community-based research to reduce cancer-related health disparities in Chicago's south suburbs.
Leading cancer research organizations to host international cancer immunotherapy conference
The Cancer Research Institute, the Association for Cancer Immunotherapy, the European Academy of Tumor Immunology, and the American Association for Cancer Research will join forces to sponsor the first International Cancer Immunotherapy Conference at the Sheraton New York Times Square Hotel in New York, Sept.

Related Cancer Reading:

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Climate Crisis
There's no greater threat to humanity than climate change. What can we do to stop the worst consequences? This hour, TED speakers explore how we can save our planet and whether we can do it in time. Guests include climate activist Greta Thunberg, chemical engineer Jennifer Wilcox, research scientist Sean Davis, food innovator Bruce Friedrich, and psychologist Per Espen Stoknes.
Now Playing: Science for the People

#527 Honey I CRISPR'd the Kids
This week we're coming to you from Awesome Con in Washington, D.C. There, host Bethany Brookshire led a panel of three amazing guests to talk about the promise and perils of CRISPR, and what happens now that CRISPR babies have (maybe?) been born. Featuring science writer Tina Saey, molecular biologist Anne Simon, and bioethicist Alan Regenberg. A Nobel Prize winner argues banning CRISPR babies won’t work Geneticists push for a 5-year global ban on gene-edited babies A CRISPR spin-off causes unintended typos in DNA News of the first gene-edited babies ignited a firestorm The researcher who created CRISPR twins defends...